Ap­peals court sides with Gilead, Kite in CAR-T patent brawl, void­ing Bris­tol My­ers’ big $1.2B award

A new twist emerged Thurs­day in the long-run­ning patent fight be­tween Juno Ther­a­peu­tics and Gilead’s Kite Phar­ma over CAR-T tech­nol­o­gy, one that gets Kite off the hook for more than $1.2 bil­lion in dam­ages.

The US Court of Ap­peals for the Fed­er­al Cir­cuit re­versed a pre­vi­ous de­ci­sion award­ing the mon­ey to Juno, rul­ing in a 19-page opin­ion that a patent owned by the Bris­tol My­ers Squibb sub­sidiary and Sloan Ket­ter­ing is in­valid. All three pan­el judges agreed with Kite’s po­si­tion, over­turn­ing a ver­dict from De­cem­ber 2019 af­ter find­ing “sub­stan­tial ev­i­dence does not sup­port the ju­ry’s ver­dict in Juno’s fa­vor.”

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER